EMEA-002966-PIP01-21
Key facts
| Active substance |
Etesevimab
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0214/2021
|
| PIP number |
EMEA-002966-PIP01-21
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Eli Lilly and Company Limited
Tel. +44 (0) 0125631500 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|